“2019 China Medical & Health Industry Development & China 4th Pharmaceutical R&D Summit" was successfully held at Chongqing International Convention & Exhibition Center on June 21,2019.

With the theme of "Calling on New Generation Intelligence, Enabling An Innovative New Journey", the Summit launched a two-day in-depth exchange. During the session, front-burner issues were heated discussed and deep analysis of industrial innovation were dug into, enabling more rapid industry development, propelling its advancement on an international level and spreading the notion of "Health in China". It is on this very conference that PharmaBlock Sciences (Nanjing), Inc. was awarded the title of "2019 Top 20 CRO in China ".

Ever since its foundation, PharmaBlock has always been focusing on design and synthesis of novel building blocks, aiming to support small molecule drug discovery. The company takes pride in providing customers with tens of thousands of various building blocks, many of which have been widely adopted by pharmaceutical chemists around the world to optimize drug candidates structures, by improving their physicochemical properties, including lowering cardio-toxicity, enhancing metabolic stability, boosting solubility etc., while expanding patent space.

In recent years, based on substantial experience and advantages accumulated in design and synthesis of building blocks, PharmaBlock has continuously strengthened process development and scale-up manufacturing capacity, established a series of advanced technological platforms including continuous flow chemistry, microreaction technology, biocatalysis, fluorination etc., promoting highly efficient and green chemical production.

"The award is an affirmative honor of PharmaBlock’s chemistry capabilities and commitment to delivery", according to Mr. Yi Li, VP of PharmaBlock , "We will continue to center on building blocks as we always do, supporting new drug R&D at all stages from discovery to development to commercialization. "